Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

The stock's high price tag could be a problem for investors looking for a big return. Summit Therapeutics (NASDAQ: SMMT) has ...

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Merck & ...

We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...

The US merchandise-trade deficit with Ireland soared to a record in March on a massive inflow of pharmaceuticals and ...

In recent months, drugmakers told Reuters they had taken the unusual step of sending more medicines by air to the US. Two of ...

At this time, I would like to welcome everyone to the Jacobs fiscal second-quarter 2025 earnings conference call. (Operator Instructions) Thank you. And I would now like to turn the conference over to ...

WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for first quarter ...